Abstract
Melatonin is an important neuroprotective factor and its receptors are expressed in the fetal brain. During normal pregnancy, maternal melatonin level increases progressively until term and is highly transferred to the fetus, with an important role in brain formation and differentiation. Maternal melatonin provides the first circadian signal to the fetus. This indolamine is also produced de novo and plays a protective role in the human placenta. In pregnancy disorders, both maternal and placental melatonin levels are decreased. Alteration in maternal melatonin level has been associated with disrupted brain programming with long-term effects. Melatonin has strong antioxidant protective effects directly and indirectly via the activation of its receptors. The fetal brain is highly susceptible to oxygenation variation and oxidative stress that can lead to neuronal development disruption. Based on that, several approaches have been tested as a treatment in case of pregnancy disorders and melatonin, through its neuroprotective effect, has been recently accepted against fetal brain injury. This review provides an overview about the protective effects of melatonin during pregnancy and on fetal brain development.
Keywords: Placenta, melatonin, preterm birth, neurogenesis disorders, neuroprotection, neural tube, fetus.
Current Pharmaceutical Design
Title:Melatonin in Pregnancy: Effects on Brain Development and CNS Programming Disorders
Volume: 22 Issue: 8
Author(s): Lucas Sagrillo-Fagundes, Eugenia Maria Assuncao Salustiano, Philippe Wong Yen, Ahmed Soliman and Cathy Vaillancourt
Affiliation:
Keywords: Placenta, melatonin, preterm birth, neurogenesis disorders, neuroprotection, neural tube, fetus.
Abstract: Melatonin is an important neuroprotective factor and its receptors are expressed in the fetal brain. During normal pregnancy, maternal melatonin level increases progressively until term and is highly transferred to the fetus, with an important role in brain formation and differentiation. Maternal melatonin provides the first circadian signal to the fetus. This indolamine is also produced de novo and plays a protective role in the human placenta. In pregnancy disorders, both maternal and placental melatonin levels are decreased. Alteration in maternal melatonin level has been associated with disrupted brain programming with long-term effects. Melatonin has strong antioxidant protective effects directly and indirectly via the activation of its receptors. The fetal brain is highly susceptible to oxygenation variation and oxidative stress that can lead to neuronal development disruption. Based on that, several approaches have been tested as a treatment in case of pregnancy disorders and melatonin, through its neuroprotective effect, has been recently accepted against fetal brain injury. This review provides an overview about the protective effects of melatonin during pregnancy and on fetal brain development.
Export Options
About this article
Cite this article as:
Sagrillo-Fagundes Lucas, Assuncao Salustiano Maria Eugenia, Yen Wong Philippe, Soliman Ahmed and Vaillancourt Cathy, Melatonin in Pregnancy: Effects on Brain Development and CNS Programming Disorders, Current Pharmaceutical Design 2016; 22 (8) . https://dx.doi.org/10.2174/1381612822666151214104624
DOI https://dx.doi.org/10.2174/1381612822666151214104624 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Autophagy in Diabetic Retinopathy
Current Neuropharmacology Preclinical Overview of WHI-07, A Novel Nucleoside Analog-based Dual- Function Microbicide
Current Medicinal Chemistry - Anti-Infective Agents Effects of Adding Large Doses of Arachidonic Acid to Docosahexaenoic Acid on Social Impairment in Individuals with Autism Spectrum Disorders
Current Psychopharmacology Administration of Exogenous Surfactant and Cytosolic Phospholipase A2α Inhibitors may Help COVID-19 Infected Patients with Chronic Diseases
Coronaviruses Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders
Current Neuropharmacology Substance P in Rheumatic Diseases
Current Rheumatology Reviews Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer’s Disease
Current Alzheimer Research Old Strategies and New Perspectives in Modulating the Endocannabinoid System
Current Bioactive Compounds Herbal Compounds with Special Reference to Gastrodin as Potential Therapeutic Agents for Microglia Mediated Neuroinflammation
Current Medicinal Chemistry MicroRNA-582-5p Reduces Propofol-induced Apoptosis in Developing Neurons by Targeting ROCK1
Current Neurovascular Research Autophagy in the Central Nervous System: Implications for Neurodegenerative Disorders
CNS & Neurological Disorders - Drug Targets Current Options and Perspectives in the Treatment of Diabetic Neuropathy
Current Pharmaceutical Design Polymeric Nanomicelles of Soluplus® as a Strategy for Enhancing the Solubility, Bioavailability and Efficacy of Poorly Soluble Active Compounds
Current Nanomedicine Anti-Inflammatory Drugs in the Treatment of Neurodegenerative Diseases: Current State
Current Pharmaceutical Design Nongenomic Actions of Thyroid Hormones: Every why has a Wherefore
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Methamphetamine and HIV Infection, Role in Neurocognitive Dysfunction
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?
Current Drug Targets Mechanisms And Prevention Of TAVI-Related Cerebrovascular Events
Current Pharmaceutical Design Cocaine and Acute Vascular Diseases
Current Drug Abuse Reviews Artificial O2 Carriers: Status in 2005
Current Pharmaceutical Design